RSLS Stock Overview
Provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ReShape Lifesciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.34 |
| 52 Week High | US$29.00 |
| 52 Week Low | US$0.30 |
| Beta | 1.92 |
| 1 Month Change | -78.68% |
| 3 Month Change | -91.01% |
| 1 Year Change | -96.67% |
| 3 Year Change | -99.98% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)
Apr 18
ReShape wins FDA clearance for device used in weight loss surgery
Aug 10Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results
Mar 31Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?
Dec 09Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?
Aug 24Shareholder Returns
| RSLS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -10.8% | -0.1% | 1.8% |
| 1Y | -96.7% | 6.3% | 9.5% |
Return vs Industry: RSLS underperformed the US Medical Equipment industry which returned 7.7% over the past year.
Return vs Market: RSLS underperformed the US Market which returned 9.6% over the past year.
Price Volatility
| RSLS volatility | |
|---|---|
| RSLS Average Weekly Movement | 104.9% |
| Medical Equipment Industry Average Movement | 9.3% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: RSLS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RSLS's weekly volatility has increased from 54% to 105% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 18 | Paul Hickey | www.reshapelifesciences.com |
ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual’s comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus.
ReShape Lifesciences Inc. Fundamentals Summary
| RSLS fundamental statistics | |
|---|---|
| Market cap | US$3.82m |
| Earnings (TTM) | -US$7.13m |
| Revenue (TTM) | US$8.01m |
0.5x
P/S Ratio-0.5x
P/E RatioIs RSLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RSLS income statement (TTM) | |
|---|---|
| Revenue | US$8.01m |
| Cost of Revenue | US$2.95m |
| Gross Profit | US$5.06m |
| Other Expenses | US$12.19m |
| Earnings | -US$7.13m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 63.17% |
| Net Profit Margin | -89.06% |
| Debt/Equity Ratio | -320.6% |
How did RSLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/01 01:39 |
| End of Day Share Price | 2025/05/01 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ReShape Lifesciences Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |